Argenx Se stock analysis
Argenx Se (1AEA) Stock Price & Analysis
1AEA Stock Chart & Stats
- Day’s Range
- EUR 840.00 - EUR 865.00
- 52-Week Range
- EUR 560.00 - EUR 920.00
- Previous Close
- EUR 875.00
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 55.24B
- Enterprise Value
- EUR 54.62B
- Total Cash (Recent Filing)
- EUR 5.18B
- Total Debt (Recent Filing)
- EUR 47.00M
- Price to Earnings (P/E)
- 45.5
- Beta
- 0.30
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 7.26
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Rapid Product Growth And Margins
Sustained product growth, driven by increasing patients served, shows expanding commercial adoption rather than reliance on a single short-term event. Strong operating margins indicate that revenue is scaling faster than expenses, supporting reinvestment and potentially durable earnings growth.
Exceptional Balance Sheet Strength
Minimal leverage and a large equity base give argenx substantial flexibility to fund research, commercial expansion and acquisitions without depending heavily on debt markets. This financial capacity is especially valuable for biotechnology programs that require sustained investment before generating revenue.
Broad Commercial And Pipeline Expansion
A growing pipeline combined with multiple potential launches can diversify argenx beyond its current marketed indications and extend its commercial platform. Additional labels, delivery options and disease areas create several avenues for patient growth and reduce dependence on one development catalyst.
Bears Say
Sharp Operating Expense Increase
The planned expense step-up materially raises the investment required to support Forte, FB102, commercial infrastructure and the broader pipeline. Even if strategically justified, this spending can pressure margins and cash generation if launches, approvals or clinical outcomes take longer than expected.
Clinical Development Setbacks
Stopping UNITY for futility removes a development opportunity and demonstrates that parts of the pipeline may not translate into successful products. Such outcomes can narrow future indication breadth, reduce the return on research spending and increase reliance on the remaining programs.
Uneven Cash Conversion History
Although cash flow improved substantially in 2025, the multiyear record remains inconsistent and operating cash flow did not fully match reported earnings. Continued investment and expansion therefore require close execution to ensure accounting profitability converts into durable internally generated cash.
Argenx Se News
1AEA FAQ
What was Argenx Se’s price range in the past 12 months?
What is Argenx Se’s market cap?
When is Argenx Se’s upcoming earnings report date?
How were Argenx Se’s earnings last quarter?
Is Argenx Se overvalued?
Does Argenx Se pay dividends?
What is Argenx Se’s EPS estimate?
How many shares outstanding does Argenx Se have?
What happened to Argenx Se’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Argenx Se?
What is the TipRanks Smart Score and how is it calculated?
Argenx Se Stock Smart Score
Company Description
Argenx Se
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Karen Massey
- Employees
- 1,863
- Website
- www.argenx.com
- Address
- Laarderhoogtweg 25, Amsterdam, NH, 1101 EB, NL
Argenx Se (1AEA) Earnings & Revenues
1AEA Company Deck
1AEA Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by 54% year-over-year product sales growth, continued momentum in both MG and CIDP, positive ALKIVIA and FB102 data, a broadening pipeline and expectations for up to five potential launches in 2027. The main challenges were the dermatomyositis confirmatory-trial requirement, the Sjögren's futility outcome, elevated planned operating expenses and limited formal revenue guidance, but these issues were outweighed by the company's commercial performance, financial strength and pipeline progress.
View all DE:1AEA earnings summaries1AEA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 1 | 5 |
| Technical Analysis | 4 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |












